NPS completes rolling NDA for Gattex in short bowel syndrome
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals reported that it has completed the submission of its new drug application (NDA) for Gattex (teduglutide) as a treatment for adults with short bowel syndrome (SBS), a condition resulting from the surgical removal of significant portions of the bowel following injury or illness.